Vol.

No.

March 29, 2024Mar 29, 2024

DOWNLOAD THE PDF

Cover Story

Rathmell: A tough budget is an opportunity to make sure NCI is “doing what is best for the American public”

Next week, NCI will announce its plans for surviving on an austere budget given to it by Congress as fiscal year 2024 approaches the six-month mark.

Capitol Hill

With reduced FY24 funding, NCI prepares to make cuts

By Matthew Bin Han Ong

Regulatory News

Exercising new powers, FDA issues Complete Response Letters based on insufficient enrollment in confirmatory trials

By Paul Goldberg

Daniel Snyder, former Washington Commanders owner, donates riverfront “château” to ACS

By Jacquelyn Cobb

BSA approves two new concepts, three reissues

Free In the Archives

Women’s History Month—How “Dr. Susan Love’s Breast Book” has remained the “bible” for women with breast cancer since 1990

By Alexandria Carolan

In Brief

Etta Pisano named senior portfolio lead at ARPA-H

Nirag Jhala named chief of the oncologic pathology at Rutgers

City of Hope Atlanta opens Blood and Marrow Transplantation and Cell Therapy Program

A. Samer Al-Homsi named system chief of blood and marrow transplant and cellular therapy at Northwell

IU Simon to establish new lung cancer research center with $20M gift

Fox Chase opens first New Jersey location in Voorhees

UF Health Proton Therapy Institute adds interactive video wall for pediatric patients

UVA, Southwest Virginia providers partner to boost CRC screening

UT Southwestern Moncrief Cancer Institute debuts second mobile screening clinic funded by Tarrant County

High school seniors win $1.8M at Regeneron science talent search 2024 for research on AI, cancer metabolism, and mathematical optimization

Clinical Roundup

Phase III Opdivo + Yervoy trial meets primary endpoint in advanced HCC

UCLA: Adding ribociclib to hormone therapy reduces the risk of breast cancer recurrence

Imfinzi regimen reduces the risk of disease progression or death in liver cancer eligible for embolization

Observational study demonstrates clinical validity and utility of OncoHost’s PROphet NSCLC test

Purdue researchers create biocompatible nanoparticles to enhance systemic delivery of cancer immunotherapy

RCSI preclinical research identifies promising drug combination for MM treatment

USC researchers find genetic variant contributing to disparities in childhood leukemia risk

UT Southwestern study identifies clustering of specific gut bacteria associated with race, ethnicity in patients

Drugs & Targets

FDA approves Elahere for FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer

FDA grants orphan drug designation to Heidelberg Pharma agent for MM

PREVIOUS ISSUE

NEXT ISSUE

Recent Issues

Volume 52 | Issue 35 - September 25, 2026